<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="chronic hepatitis C infection has undergone a paradigm shift from" exact="alpha" post="interferon to direct-acting antiviral (DAA) therapy. However, resistance to"/>
 <result pre="chronic hepatitis C infection has undergone a paradigm shift from" exact="alpha" post="interferon to directly acting antiviral (DAA) therapy.[1] However, resistance"/>
 <result pre="co-infection, high body mass index, presence of hepatic steatosis, and" exact="alcohol" post="consumption. Patients with cirrhosis can decompensate with complications like"/>
 <result pre="ranging from 10 to 20%. In 1998, the oral drug" exact="ribavirin" post="was added to interferon. The therapeutic response rates increased"/>
 <result pre="this drug. In 2011, two protease inhibitors were introduced namely" exact="boceprevir" post="and telaprevir.[47] Treatment of chronic HCV with PEG-IFN and"/>
 <result pre="boceprevir and telaprevir.[47] Treatment of chronic HCV with PEG-IFN and" exact="ribavirin" post="and, more recently, with PEG-IFN plus ribavirin and first-generation"/>
 <result pre="with PEG-IFN and ribavirin and, more recently, with PEG-IFN plus" exact="ribavirin" post="and first-generation protease inhibitors (Telaprevir and Boceprevir) for HCV-1,"/>
 <result pre="Comments NS3/4A protease inhibitors 1st generation: Telaprevir, Boceprevir 2nd generation:" exact="Simeprevir" post="Next generation drugs: Glecaprevir, Grazoprevir, Paritaprevir, Voxilaprevir Bind to"/>
 <result pre="barriers to resistance. NS5A inhibitors Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Pibrentasvir," exact="Velpatasvir" post="Interact with domain 1 of the NS5A dimer, although"/>
 <result pre="may interact with HIV antiretrovirals (nucleoside reverse transcriptase inhibitors) and" exact="ribavirin" post="Can cause mitochondrial toxicity Nucleos(t) ide analog NS5B polymerase"/>
 <result pre="Can cause mitochondrial toxicity Nucleos(t) ide analog NS5B polymerase inhibitors" exact="Sofosbuvir" post="These are incorporated into the nascent RNA chain and"/>
 <result pre="inhibitor V36M, T54S, R155K 1a T54A/S, V55A, A156S, V170A 1b" exact="Telaprevir" post="NS3/4A protease inhibitor V36M, R155K 1a V36A, T54A, A156S"/>
 <result pre="NS3/4A protease inhibitor V36M, R155K 1a V36A, T54A, A156S 1b" exact="Simeprevir" post="NS3/4A protease inhibitor R155K, D168E/V 1a Q80R, D168E/V 1b"/>
 <result pre="Simeprevir NS3/4A protease inhibitor R155K, D168E/V 1a Q80R, D168E/V 1b" exact="Paritaprevir" post="NS3/4A protease inhibitor D168A/V/Y 1a Y56H, D168V 1b D168V"/>
 <result pre=" Ombitasvir NS5A inhibitor M28V, Q30R 1a Y93H 1b L28V 4d" exact="Sofosbuvir" post="NS5B nucleotide polymerase inhibitor S282T 2 L159F, V321A 3"/>
 <result pre="management by impacting the duration of therapy and/or inclusion of" exact="ribavirin" post="or result in selection of alternative therapy. However, at"/>
 <result pre="for 12 weeks of sofosbuvir/velpatasvir. If Y93H is present, weight-based" exact="ribavirin" post="should be added or sofosbuvir/velpatasvir/voxilaprevir should be used. I,"/>
 <result pre="should be added or sofosbuvir/velpatasvir/voxilaprevir should be used. I, A" exact="Daclatasvir" post="plus sofosbuvir  NS5A RAS testing is recommended for genotype"/>
 <result pre="added or sofosbuvir/velpatasvir/voxilaprevir should be used. I, A Daclatasvir plus" exact="sofosbuvir" post=" NS5A RAS testing is recommended for genotype 3-infected, treatment-experienced"/>
 <result pre="treatment-experienced patients without cirrhosis being considered for 12 weeks of" exact="daclatasvir" post="plus sofosbuvir. If Y93H is present, weight-based ribavirin should"/>
 <result pre="weeks of daclatasvir plus sofosbuvir. If Y93H is present, weight-based" exact="ribavirin" post="should be added.  NS5A RAS testing is recommended for"/>
 <result pre="treatment-naive patients with cirrhosis being considered for 24 weeks of" exact="daclatasvir" post="plus sofosbuvir. If Y93H is present, treatment should include"/>
 <result pre="I, A Paritaprevir/ritonavir/ombitasvir with dasabuvir±weight-based ribavirin, or paritaprevir/ritonavir/ombitasvir + weight-based" exact="ribavirin" post=" RAS testing is not recommended for genotype 1- or"/>
 <result pre="-experienced patients being considered for therapy with paritaprevir/ritonavir/ombitasvir with dasabuvir±weight-based" exact="ribavirin" post="or paritaprevir/ritonavir/ombitasvir + weight-based ribavirin, respectively. I, A Sofosbuvir/velpatasvir"/>
 <result pre="49JacobsonIMPawlotskyJMAfdhalNHDusheikoGMFornsXJensenDMet al.A practical guide for the use of Boceprevir and" exact="Telaprevir" post="for the treatment of hepatitis CJ Viral Hepatitis201219Suppl 2126"/>
 <result pre="resistance in genotype 1-6 hepatitis C virus-infected subjects treated with" exact="sofosbuvir" post="in phase 2 and 3 clinical trialsClin Infect Dis20145916667425266287"/>
</results>
